Innovation Ventures

Partnering Opportunities

• Genetics Immunology

  Complement 5a increases inflammation in Hunter Syndrome

  Complement 5a increases inflammation in Hunter Syndrome

• Pulmonology

  Repurposing Barasertib for Idiopathic Pulmonary Fibrosis

  Repurposing a phase I/II compound (AURKB inhibitor - barasertib) for idiopathic pulmonary fibrosis therapy.

• Immunology

  CAR-NK Therapy for Lupus

  Human Natural Killer cells expressing chimeric antigen receptor that targets aberrant immune system signaling that is involved in auto-antibody production associated with Systemic Lupus Erythematosus.

• Neurodegenerative Diseases

  Restoring acid-β-glucosidase activity by non-inhibitory small molecule chaperones

  Restore GCase activity in the brain for Gaucher and Parkinson's

• Neurology

  Multi-Frequency Encoded Source Imaging

  A new imaging technology to localize and visualize electrical and/or magnetic signals in two or more frequency ranges.

• Neurology

  Histone Deacetylase 3 Inhibitors for Treating Demyelinating Diseases

  HDAC3 inhibitors enhance myelin repair in white matter injury and demyelinating diseases

• Pulmonology

  Serum Biomarkers and Algorithm of Lung Decline in Cystic Fibrosis

  Novel serum protein biomarkers and functional data analysis-based algorithm used to develop a predictive test for lung function decline.

• Infectious Disease

  Bivalent VLP Ebola Vaccine

  Bi-valent spherical virus like particle (VLP) vaccine against Ebola virus.

• Pulmonology

  Method of Treating Cystic Fibrosis with Src Kinase Inhibitors

  Scientists have shown that src kinase inhibitors are effective at treating CF patients with a frame deletion of F508 in the CFTR gene.

• Asthma

  Repurposing of Cysteamine for the Treatment of Asthma

  Cysteamine, an FDA approved treatment for cystinosis, has been shown to be an effective oral treatment for steroid resistant asthma including airway hyperresponsiveness (AHR) and airway inflammation.